Your session is about to expire
← Back to Search
Radium-223 for Recurrent Prostate Cancer
Study Summary
This trial is studying how Radium-223 affects men with rising PSA but no evidence of cancer on conventional CT or bone scan, but positive findings on PET or molecular imaging in the bones.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 29 Patients • NCT02278055Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery in the last 28 days.My PET scan shows possible prostate cancer spread to bones, but not to organs.My PET scan shows signs of internal organ disease.I have recovered from side effects of my previous cancer treatments.I have not had an organ transplant that requires immunosuppression.I have been treated with specific radioactive drugs before.I agree to use effective birth control during and 6 months after the study.I am taking medications that can change my PSA levels, like finasteride.I haven't taken daily steroids for more than 2 weeks in the last month.I haven't had any other cancers except for skin cancer or bladder cancer in situ in the last 3 years.My kidney function is normal based on tests.My scans show no signs of prostate cancer spread.My liver function tests are within the required range.I can carry out all my daily activities without help.I am 18 years old or older.I do not have HIV or any condition that weakens my immune system.I have had chemotherapy before.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you share any other research that has looked at Radium-223?
"Radium-223 has 15 ongoing trials, 3 of which are in Phase 3. Some of these studies are based in Kuala Lumpur or WP Kuala Lumpur, but there are 83 total locations running clinical trials for Radium-223."
How is Radium-223 most commonly used?
"Radium-223, while most commonly used to treat dentures, can also be used as a form of parenteral nutrition or to address trace element deficiencies and total dental decay."
Are there any patients who can still join this clinical trial?
"That is correct. The clinical trial indicated on clinicaltrials.gov is still actively looking for participants. This study was first posted on September 22nd, 2020 and was last updated on November 9th, 2020. Currently, 26 individuals are needed to enroll at 1 site."
How many individuals are taking part in this research project?
"That is accurate, the trial detailed on clinicaltrials.gov is presently recruiting patients. This experiment was initially posted on September 22nd 2020 and was most recently updated on November 9th 2020. 1 medical facility is looking to enroll 26 individuals in total."
Does Radium-223 have a high potential to harm patients?
"Radium-223 receives a 2 for safety from our Power team because, although Phase 2 trials have not yet yielded data to support efficacy, there is some evidence that it is safe."
Share this study with friends
Copy Link
Messenger